Avanos Medical (NYSE:AVNS) Downgraded by Wall Street Zen to Buy

Avanos Medical (NYSE:AVNS) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

AVNS has been the subject of a number of other reports. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Avanos Medical currently has an average rating of “Reduce”.

Avanos Medical Stock Down 2.6%

AVNS stock opened at $14.12 on Friday. The company has a market capitalization of $656.44 million, a P/E ratio of -8.93 and a beta of 1.09. The company has a current ratio of 2.15, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. Avanos Medical has a twelve month low of $9.30 and a twelve month high of $15.68. The firm has a 50 day simple moving average of $13.05 and a 200-day simple moving average of $12.10.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, equities research analysts predict that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its stake in shares of Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after buying an additional 1,423 shares in the last quarter. Versant Capital Management Inc raised its position in Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after purchasing an additional 2,307 shares in the last quarter. Wexford Capital LP acquired a new stake in Avanos Medical during the third quarter valued at approximately $70,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after buying an additional 5,083 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.